Navigation Links
Atypical form of Alzheimer's disease may be present in a more widespread number of patients
Date:5/1/2014

JACKSONVILLE, Fla. Neuroscientists at Mayo Clinic in Florida have defined a subtype of Alzheimer's disease (AD) that they say is neither well recognized nor treated appropriately.

The variant, called hippocampal sparing AD, made up 11 percent of the 1,821 AD-confirmed brains examined by Mayo Clinic researchers suggesting this subtype is relatively widespread in the general population. The Alzheimer's Association estimates that 5.2 million Americans are living with AD. And with nearly half of hippocampal sparing AD patients being misdiagnosed, this could mean that well over 600,000 Americans make up this AD variant, researchers say.

In an oral presentation at the annual meeting of the American Academy of Neurology in Philadelphia, scientists say hippocampal sparing AD often produces symptoms that are substantially different from the most commonly known form of AD, which affects the hippocampus, the center of memory.

The patients, mostly male, are afflicted at a much younger age, and their symptoms can be bizarre behavioral problems such as frequent and sometimes profane angry outbursts, feelings that their limbs do not belong to them and are controlled by an "alien" unidentifiable force, or visual disturbances in the absence of eye problems, researchers say.

They also decline at a much faster rate than do patients with the most common form of AD.

"Many of these patients, however, have memories that are near normal, so clinicians often misdiagnose them with a variety of conditions that do not match the underlying neuropathology," says the study's lead author, Melissa Murray, Ph.D., an assistant professor of neuroscience at Mayo Clinic in Florida.

Many of these patients are diagnosed with frontotemporal dementia, a disorder characterized by changes in personality and social behavior, or corticobasal syndrome, characterized by movement disorders and cognitive dysfunction. Language dysfunction is also more common in hippocampal sparing AD, although patients do not have vocal or hearing deficits.

"What is tragic is that these patients are commonly misdiagnosed and we have new evidence that suggests drugs now on the market for AD could work best in these hippocampal sparing patients possibly better than they work in the common form of the disease," Dr. Murray says.

The researchers benefit greatly from one of the largest brain banks in the country more than 6,500 brain donations as well as a collaborative environment between neuroscience research and neurology at Mayo Clinic, she says.

Both hallmark proteins of AD amyloid beta (Aβ), which forms Aβ plaques, and tau, which produces tangles are found across all subtypes of AD, including hippocampal sparing AD. The researchers developed a mathematical algorithm to classify AD subtypes using tangle counts. "What is fascinating is that all the AD patient subtypes had the same amount of amyloid, but for some reason tau tangles were found in strategic cortical regions disproportionate to the hippocampus."

In these patients, tau preferentially damages and eventually destroys neurons in parts of the brain involved in behavior, motor awareness and recognition, as well as use of speech and vision, Dr. Murray says.

She says she hopes this research, the second high-profile Mayo study to highlight hippocampal sparing AD, will "open the minds" of clinicians who are trying to diagnose dementia, helping them understand that loss of memory is not present in every AD patient.

"Our studies support the notion that dementia related to AD does not necessarily equate to a loss of memory, and points to the need for more research in amyloid and tau imaging biomarkers to help clinicians accurately diagnose AD regardless of subtype," Dr. Murray says.


'/>"/>

Contact: Kevin Punsky
newsbureau@mayo.edu
507-284-5005
Mayo Clinic
Source:Eurekalert

Related medicine news :

1. TrueWholesaleJewelry.com Launches Atypical Consumer Direct Wholesale Jewelry Site
2. Immunoglobulins Market to 2019 - Demand in Primary Immunodeficiency And CIDP Potentially Supplemented by Approval for Alzheimers Disease Available at ResearchMoz.us
3. Indoor Memory Maker Triathlon Raises Funds for Alzheimers
4. Witnessing, Experiencing Traumatic Events May Worsen Heart Disease
5. Pulse pressure elevation could presage cerebrovascular disease in Alzheimers patients
6. Mayo Clinic offers newly approved treatment for acid reflux disease
7. Spouses of Cancer Patients May Have Raised Risk of Heart Disease, Stroke
8. Huntingtons Disease Linked to Reduced Cancer Risk in Study
9. AstraZeneca and DNDi to collaborate on drug screening for neglected tropical diseases
10. Role of Screening, Monitoring in Early Kidney Disease Unclear
11. No Proof That Gum Disease Causes Heart Disease, Experts Say
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/20/2017)... ... February 20, 2017 , ... A new ... women are called back for additional examinations without sacrificing cancer detection, according to ... 2011, the U.S. Food and Drug Administration approved digital breast tomosynthesis (DBT) for ...
(Date:2/20/2017)... (PRWEB) , ... February 21, 2017 , ... Nancy ... offering readers a way to “ Getting Over the Bump in the Road ” ... and lessons learned on how to cope with the ups and downs experienced by ...
(Date:2/20/2017)... ... ... Silverado today is pleased to announce that it has entered into a management ... Alexandria, Virginia. The new community is expected to open its doors in the first ... three-story community with underground parking – located on King Street –will serve 66 people ...
(Date:2/20/2017)... ... February 20, 2017 , ... ... 213-8818 , Orbita, Inc., a leading provider of innovative software for connected home ... patient engagement and optimizing care journey management for home healthcare. , Built ...
(Date:2/20/2017)... ... February 20, 2017 , ... ... a cloud-based self-service technology that runs on the Posiflex XT-series of touch screen ... during HIMSS17 in Orlando, Florida. The terminal provider Posiflex is helping ...
Breaking Medicine News(10 mins):
(Date:2/21/2017)... Feb. 21, 2017 Cognitive Computing for ... is allowing a previously unattainable level of personalized ... this ability, it is anticipated that the Global ... Billion by 2022. The growth of the market ... computing platforms, rising installation of cognitive computing software ...
(Date:2/21/2017)... Feb. 21, 2017  /PR Newswire/ -- UBM Medica,s ... announce the launch of Modern Retina ( ... retina specialists. Built upon the success of ... on the latest innovations in the areas of retinal ... management. By meeting current informational needs and filling existing ...
(Date:2/21/2017)... Scientists From Two Companies to Accelerate Development ... ... STEER, creator of advanced materials platform technologies that effectively ... pharmaceuticals, food and nutraceuticals, biomaterials and biorefining, today announced a ... , a leading science & technology company, on ...
Breaking Medicine Technology: